News
-
-
PRESS RELEASE
Secarna Pharmaceuticals and Protalix Biotherapeutics Enter into Collaboration and Option Agreement
Secarna Pharmaceuticals and Protalix Biotherapeutics enter into collaboration and option agreement to develop oligonucleotide therapies for rare renal indications. Combine expertise in rare diseases and biologics -
-
PRESS RELEASE
Secarna Pharmaceuticals enters discovery and co-development agreement with Scenic Biotech to develop disease-modifying oligonucleotide therapy against a novel drug target
Secarna Pharmaceuticals partners with Scenic Biotech to develop disease-modifying oligonucleotide therapy against novel drug target, leveraging expertise and synergies for new treatments -
-
PRESS RELEASE
Secarna Pharmaceuticals and Vect-Horus Announce Research Collaboration to Advance Systemic Delivery of RNA-Targeted Therapeutics for CNS Disorders
Secarna Pharmaceuticals and Vect-Horus announced a research collaboration to advance systemic delivery of RNA-targeted therapeutics for CNS disorders, combining expertise in RNA therapeutics and advanced delivery technologies -
-
PRESS RELEASE
Secarna Pharmaceuticals to present new data and clinical strategy for lead antisense oligonucleotide program SECN-15 at ASCO 2025
Secarna Pharmaceuticals to present new data and clinical strategy for SECN-15 at ASCO 2025. Targeting NRP1 with antisense oligonucleotides for solid cancers. Promising therapeutic approach -
-
